This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): quetiapine fumarate sustained/extended release, Seroquel SR, FK949E
Description: BioMedTracker has separate drug profiles for the regular release and extended release (XR) formulationsof Seroquel. Please also see Seroquel.
Seroquel XR is an extended release formulation of Seroquel (quetiapine fumarate), which is a psychotropic agent belonging to the chemical class of dibenzothiazepine derivatives. Seroquel is an atypical antipsychotic with a higher affinity for the serotonin 5-HT2 receptor relative to its affinity for the dopamine D-2 receptor. Though the exact mechanism is unclear (either due to a difference in affinities for such receptors or fast dissociation from the D-2 receptor), atypical antipsychotics are able to produce an antipsychotic effect (through blockade of D-2 receptors in the ventral striatum) with fewer extrapyramidal motor function side effects (or EPSs, which are caused by blockade of D-2 receptors in the dorsal striatum).
Historical revenue for Seroquel and Seroquel XR through 2014 is recorded under Seroquel. As of Q1 2015, revenues for Seroquel IR are not given and so revenues will only be recorded under the XR profile. Revenue forecast recorded under Seroquel as well.
In December 2010, Astellas announced that it agreed with AstraZeneca upon an extension of its existing Seroquel licence to include Seroquel extended release Tab. Under the terms of the extended license, Astellas is granted by AstraZeneca an exclusive right for development, formulation, packaging, sale and promotion for Seroquel extended release Tab in Japan. The term of the license is ten years after Seroquel extended release Tab launch.
Partners: Astellas Pharma, Inc.
Seroquel XR News
Additional information available to subscribers only: